Moreover, the treatment with all-trans retinoic acid (ATRA), clinically used for acute promyelocytic leukemia (APL), can induce CD38 upregulation in CD38low adult T-cell leukemia (ATL) cells, making them susceptible to CD38 CAR-T cells [138]. The gene discussed is CD38; the disease is T-cell leukemia.